Dear Members and Colleagues,

WMSHP would like to announce a Live Virtual Educational and Continuing Education (CE) Program for pharmacists and technicians.

Please join us for a two part educational event on Thursday July 30, 2020, at 6 pm EST.

Registration is required for the event.

*Note: Registration is due by no later than July 26th when the site will close. Register early as space is limited.*

The event is free for WMSHP members. The cost for Non-members is $5.

**Members**

Registration link: [https://www.surveymonkey.com/r/07302020](https://www.surveymonkey.com/r/07302020)

**Nonmembers**

Complete both links below:

Registration Link: [https://www.surveymonkey.com/r/07302020](https://www.surveymonkey.com/r/07302020)

Payment Link: [http://wmshp.org/event-registration.php](http://wmshp.org/event-registration.php)
Program Agenda:
Welcome and Introductions: Vaiyapuri Subramaniam, PharmD, MS; President, WMSHP; Seminar Moderator

6 pm: Pre-Symposium Non CE

“Influenza: Cardiovascular Risks and Considerations during the COVID-19 Pandemic”

Presenter: Ferdaus Hassan, PhD
Medical Science Liaison (DC/MD/VA)
Sanofi Pasteur, US Medical Affairs

6:30 pm: Symposium CE Program:

Moderator: Ashok Ramalingam, PhD, RPh; President Elect, WMSHP & Chair, Program Committee.

"The ABC’s of CAT: An update on the treatment of cancer-associated thrombosis”

Faculty/Presenter: Amy Ives, PharmD, BCPS
Assistant Professor, School of Pharmacy, University of Maryland, Baltimore, MD

Learning Objectives (Pharmacists): At the completion of this knowledge-based activity, the participant will be able to:

1. List the host and tumor factors that predispose an individual to thrombosis.
2. Discuss the historical limitations of treating cancer-associated thrombosis.
3. Examine the literature regarding the use of DOACs in cancer-associated thrombosis.

Learning Objectives (Pharmacy Technicians): At the completion of this knowledge-based activity, the participant will be able to:

1. List the host and tumor factors that predispose an individual to thrombosis.
2. Discuss the historical limitations of treating cancer-associated thrombosis.
3. Examine the literature regarding the use of DOACs in cancer-associated thrombosis.

Universal Activity Number (UAN): 0025-9999-20-037-L01-P; 0025-9999-20-037-L01-T
Technical requirements: https://support.zoom.us/hc/en-us/articles/360043484511-System-requirements-for-Virtual-Background

Acknowledgements and thanks for the success of the Program to the presenter and faculty, Dr. Ferdaus Hassan, Dr. Amy Ives, and the WMSHP Program, Membership and Communication Committees.